TREA

Method for treatment of advanced solid tumors

Follow

Information

  • Patent Grant
  • 9370535
  • Patent Number
    9,370,535
  • Date Filed
    Wednesday, May 9, 2012
    12 years ago
  • Date Issued
    Tuesday, June 21, 2016
    8 years ago
Information
Abstract
The present invention relates to the use of Volasertib or a salt thereof or a hydrate thereof in combination with Cisplatin or Carboplatin or a salt thereof or a hydrate thereof for treating patients suffering from advanced and/or metastatic solid tumors.
Description

The present invention relates to the use of Volasertib or a salt thereof or a hydrate thereof in combination with Cisplatin or Carboplatin or a salt thereof or a hydrate thereof for treating patients suffering from advanced and/or metastatic solid tumours.


BACKGROUND OF THE INVENTION

Most advanced and/or metastatic solid tumours are incurable despite the availability of a variety of established treatment modalities like surgery, cytotoxic drugs, radiation therapy, and combinations of these. Objective responses in patients with advanced disease, though frequently seen using these treatments, are often followed by tumour progression and death. Therefore the search for new therapeutic strategies has become an urgent priority.


The efficacy of chemotherapeutic agents can be improved by combining anti-cancer drugs with different mode of action as well as by improving the dosage schedule. Even if the concept of combination therapies and improved dosage schedules already has been suggested, there is still a need for new and efficient therapeutic concepts for the treatment of cancer diseases, which show advantages over standard therapies.


Volasertib is a highly potent and selective inhibitor of the serine-threonine Polo like kinase 1 (Plk1), a key regulator of cell-cycle progression. Volasertib is a dihydropteridinone derivative with distinct pharmacokinetic (PK) properties. The problem underlying this invention was to develop improved dosage schedules for combination therapy of advanced and/or metastatic solid tumours.


Volasertib (I) is known as the compound N-[trans-4-[4-(cyclopropylmethyl)-1-piperazinyl]cyclohexyl]-4-[[(7R)-7-ethyl-5,6,7,8-tetrahydro-5-methyl-8-(1-methylethyl)-6-oxo-2-pteridinyl]amino]-3-methoxy-benzamide,




embedded image


This compound is disclosed in WO 04/076454. Furthermore, trihydrochloride salt forms and hydrates thereof are known from WO 07/090844. They possess properties which make those forms especially suitable for pharmaceutical use. The above mentioned patent applications further disclose the use of this compound or its monoethanesulfonate salt for the preparation of pharmaceutical compositions intended especially for the treatment of diseases characterized by excessive or abnormal cell proliferation.


Cisplatin (cis-diamminedichloroplatinum(II) (CDDP) (trade names Platinol and Platinol-AQ) is a chemotherapy drug. It is used to treat various types of cancers, It reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis.


Carboplatin (cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II) (trade names Paraplatin and Paraplatin-AQ) is a chemotherapy drug used against different forms of tumours. Carboplatin interact with DNA, similar to the mechanism of alkylating agents.







DETAILED DESCRIPTION OF THE INVENTION

In clinical trials with patients suffering suffering from advanced and/or metastatic solid tumours including NSCLC (non small cell lung cancer), sarcoma, colorectal cancer and melanoma it has been found that high dosages of Volasertib or a salt thereof or a hydrate thereof can be administered in combination with high dosages of cisplatin or carboplatin both having a profile of side effects (myelosuppression) which is overlapping to that of Volasertib without potentiation of those side effects.


Therefore, a first object of the present invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 to 500 mg, preferably 300 or 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of 50 to 100 mg/m2 body surface area (BSA), preferably 75 to 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle,
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule I).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule II).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of 75 mg/m2 BSA of Cisplatin at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule III).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule IV).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of 75 mg/m2 BSA of Cisplatin at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule V).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 to 500 mg, preferably 300 or 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of Carboplatin at a dose targeting AUC (area under the concentration versus time curve)=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule VI).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of Carboplatin at a dose targeting AUC=6 mg·min/mL at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule VII).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 300 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of Carboplatin at a dose targeting AUC=5 mg·min/mL at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule VIII).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of Carboplatin at a dose targeting AUC=6 mg·min/mL at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule IX).


Another object of the invention relates to a method of treating patients suffering from advanced and/or metastatic solid tumours characterized by the

    • a) administration of 350 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle and
    • b) administration of Carboplatin at a dose targeting AUC=5 mg·min/mL at one day within the same treatment cycle
    • to a patient suffering from advanced and/or metastatic solid tumours (dosage schedule X).


For all of the above given dosage schedules, the preferred treatment cycles are 14, 21 or 28 day per treatment cycle, more preferably it is a 21 day treatment cycle. Volasertib and Cisplatin or Volasertib and Carboplatin can be administered at the same day or at different days during the treatment cycle. Preferably the compounds are administered at the same day. Preferably the compounds are administered at the same time or consecutively with a short break (about 30 min) between the administrations. For example, as first medicament Cisplatin or Carboplatin is administered and after a 30 min break between the end of the administration of Cisplatin or Carboplatin Volasertib is administered.


The primary determinant of carboplatin clearance is glomerular filtration rate (GFR). GFR is a parameter of the renal function and is often decreased in elderly patients. Dosing formulas incorporating estimates of GFR to provide predictable carboplatin plasma AUCs should be used, especially in elderly patients, to minimize the risk of toxicity.


The dosing of carboplatin by target AUC is described in the current drug label. A simple formula for calculating dosage, based upon a patients glomerular filtration rate (GFR in mL/min) and carboplatin injection target area under the concentration versus time curve (AUC in mg/mL·min), has been proposed by Calvert Based on the Calvert formula, the Carboplatin doses can be calculated as:

Total Carboplatin Dose (mg)=(target AUC)×(GFR+25)[Calvert formula]


If a patient's GFR is estimated based on serum creatinine measurements by the IDMS (Isotope Dilution Mass Spectrometry) method, FDA recommends that physicians consider capping the dose of carboplatin for desired exposure (AUC) to avoid potential toxicity due to overdosing as follows:


The maximum dose is based on a GFR estimate that is capped at 125 mL/min for patients with normal renal function. No higher estimated GFR values should be used.

  • For a target AUC=6, the maximum dose is 6×150=900 mg
  • For a target AUC=5, the maximum dose is 5×150=750 mg
  • For a target AUC=4, the maximum dose is 4×150=600 mg


Another object of the invention refers to Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof for the use in treating advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours characterized in that Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof is administered according to one of the dosage schedules I to X.


Another object of the invention refers to Cisplatin for the use in treating advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours characterized in that Cisplatin is administered according to one of the dosage schedules I to X.


Another object of the invention refers to Carboplatin for the use in treating a advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours characterized in that Carboplatin is administered according to one of the dosage schedules I to X.


Another object of the invention refers to the use of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof for the manufacture of a medicament for treating advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours wherein the medicament is prepared for administration according to one of the dosage schedules I to X.


Another object of the invention refers to the use of Cisplatin or a pharmaceutically acceptable salt thereof or a hydrate thereof for the manufacture of a medicament for treating advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours wherein the medicament is prepared for administration according to one of the dosage schedules I to X.


Another object of the invention refers to the use of Carboplatin or a pharmaceutically acceptable salt thereof or a hydrate thereof for the manufacture of a medicament for treating advanced and/or metastatic solid tumours in patients suffering from advanced and/or metastatic solid tumours wherein the medicament is prepared for administration according to one of the dosage schedules I to X.


Another object of the invention is a pharmaceutical composition comprising an effective amount of Volasertib and an effective amount of Cisplatin together with an instruction for administration of both active ingredients to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and/or Cisplatin is to be administered according to the above mentioned dosage schedules I to X.


Another object of the invention is a pharmaceutical composition comprising an effective amount of Volasertib and an effective amount of Carboplatin together with an instruction for administration of both active ingredients to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and/or Carboplatin is to be administered according to the above mentioned dosage schedules I to X.


Another object of the invention is a pharmaceutical composition comprising an effective amount of Volasertib together with an instruction for administration of Volasertib and Cisplatin to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and Cisplatin is to be administered according to the above mentioned dosage schedules I to X.


Another object of the invention is a pharmaceutical composition comprising an effective amount of Volasertib a together with an instruction for administration of Volasertib and Carboplatin to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and Carboplatin is to be administered according to the above mentioned dosage schedules I to X.


Another object of the invention is a pharmaceutical kit, comprising a first compartment which comprises an effective amount of Volasertib and a second compartment which comprises an effective amount of Cisplatin, together with an instruction for administration of both active ingredients to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and Cisplatin is to be administered according to one of the above mentioned dosage schedules I to X.


Another object of the invention is a pharmaceutical kit, comprising a first compartment which comprises an effective amount of Volasertib and a second compartment which comprises an effective amount of Carboplatin, together with an instruction for administration of both active ingredients to a patient suffering from advanced and/or metastatic tumours, wherein according to said instruction Volasertib and Carboplatin is to be administered according to one of the above mentioned dosage schedules I to X.


This treatment cycle can be repeated as long as patients are eligible for repeated cycles, i.e. until progression of disease, or unacceptable toxicity and as long as neither patient nor investigator requests treatment discontinuation. If platinum treatment needs to be stopped the patient might be switched to Volasertib monotherapy


The instruction for administration may be in any form suitable for pharmaceuticals, e.g. in form of a leaflet added to the dosage form within secondary packaging or an imprint on the primary or secondary packaging.


Dosages/Volasertib:


For intraveneous treatment Volasertib may be administered to the human patient in a daily dose of 300 to 500 mg/application, preferably 300 or 350 mg/application. For instance, Volasertib can be administered as a slow intravenous infusion over several hours, e.g. over about 1, 2, 4, 6, 10, 12 or 24 hours, preferably about 1 or 2 hours.


However, it may optionally be necessary to deviate from the dosage amounts specified for Volasertib, depending on the body weight or method of administration, the individual response to the medication, the nature of the formulation used and the time or interval over which it is administered. Thus, in some cases, it may be sufficient to use less than the minimum quantity specified above, while in other cases the upper limit specified will have to be exceeded. When large amounts are administered it may be advisable to spread them over the day in a number of single doses.


Dosage Forms and Formulation Aspects


Regarding any aspects of the invention for Volasertib pharmaceutically acceptable salts or hydrates thereof may be used, preferably trihydrochloride salt forms and hydrates thereof as disclosed in WO 07/090844. Dosages or amounts of the actives provided in the context of this invention refer in any case to the free base equivalent, that is Volasertib in the free base form.


The term “therapeutically effective amount” shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue system, animal or human that is being sought by a researcher or clinician, resulting in a beneficial effect for at least a statistically significant fraction of patients, such as a improvement of symptoms, a cure, a reduction in disease load, reduction in tumor mass, extension of life, or improvement in quality of life. For Volasertib the therapeutically effective amount within the meaning of the present invention is between 300 and 500 mg per day of administration. For Cisplatin the therapeutically effective amount within the meaning of the present invention is between 50 and 100 mg/m2 BSA per day of administration. For Cisplatin the therapeutically effective amount within the meaning of the present invention is between 50 and 100 mg/m2 BSA per day of administration. For Carboplatin the therapeutically effective amount within the meaning of the present invention is calculation according to the Calvert formula:

Total Carboplatin Dose (mg)=(target AUC)×(GFR+25)[Calvert formula].


Day 1 of a e.g. 21 day treatment cycle is defined as that day at which the first dose of Volasertib is administered.


The term “advanced and/or metastatic solid tumours” is defined as histologically or cytologically confirmed diagnosis of advanced, non resectable and/or metastatic relapsed or refractory solid malignant tumour, not amenable to standard therapy or for which no therapy of proven efficacy exists.


In accordance with the present invention Volasertib, Cisplatin and Carboplatin may be administered by parenteral (e.g. intramuscular, intraperitoneal, intravenous, transdermal or subcutaneous injection), preferably intravenous application, and may be formulated, alone or together, in suitable dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles appropriate for each route of administration. Dosage forms and formulations of both actives suitable within the present invention are known in the art. For instance, such dosage forms and formulations include those disclosed for Volasertib in WO 2006/018221.


The following Examples serve to illustrate the invention without restricting it:


EXAMPLE 1
Clinical Trial

Sequential cohorts of three to six patients (pts) received a single 2-hour infusion of Volasertib (V) in combination with Cisplatin (Cis) (arm A) or Carboplatin (Ca) (arm B), on day 1 every 3 weeks. Cis and Ca were given for up to six cycles (Cy), V was continued until disease progression or unacceptable toxicity.


Results:


46 patients have received Volasertib in combination with either Cisplatin or Carboplatin. The maximum tolerated dose for volasertib in combination with cisplatin or carboplatin in patients with advanced and/or metastatic solid tumours was at or above 300 mg. Patients have received between one and 16 cycles of treatment with volasertib, with a median (range) of three (one, six) cycles in combination with cisplatin and two (one, six) cycles in combination with carboplatin


Efficacy


Four partial responses (PR) have been observed: two in patients with CHOP-resistant follicular dendritic reticulum cell sarcoma in arm A (dose level [DL] A2, A4), one in a heavily-pretreated head and neck carcinoma in arm B (DL B4), and one in a patient with pretreated lung cancer (DL A5)

    • one patient with dendritic reticulum cell sarcoma (DL A2) achieved a PR, remaining on treatment until discontinuation at the end of cycle 15 due to progressive disease (PD)
    • another patient with dendritic reticulum cell sarcoma (DL A4; volasertib dose reduced to 200 mg from fifth cycle onwards due to febrile neutropenia) had stable disease (SD) at first evaluation and relevant tumor shrinkage at second evaluation. This patient achieved PR at cycle 4, and remains on treatment in cycle 16
    • one patient with hypopharynx carcinoma (DL B4; volasertib dose reduced to 200 mg in cycle 2 due to DLT in cycle 1) achieved a PR in cycle 2, which was confirmed in cycle 4. The patient continues to have PR in cycle 12
    • one patient with lung adenocarcinoma (DL A5) is receiving treatment in cycle 4 having achieved a PR in cycle 2 that has yet to be confirmed.


These results demonstrate the beneficial effect of the combined administration of Volasertib and Cisplatin or Volasertib and Carboplatin according to the dosage schedules I to X.

Claims
  • 1. A method of treating advanced and/or metastatic solid tumours, comprising administering 300 to 500 mg Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof to a patient at one day during a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle in combination with b) 50 to 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle or Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle, to a patient suffering from advanced or metastatic solid tumours.
  • 2. The method according to claim 1, comprising administering a dosage schedule (I) comprising or consisting of a) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle andb) 50 to 100 mg/m2 BSA of Cisplatin at one day within the same treatment cycle, to a patient suffering from advanced or metastatic solid tumours.
  • 3. The method according to claim 1, comprising administering a dosage schedule (I) comprising or consisting of a) 300 to 500 mg of Volasertib or a pharmaceutically acceptable salt thereof or a hydrate thereof at one day within a 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or 31 day treatment cycle andb) Carboplatin at a dose targeting AUC=4 mg·min/mL to AUC=6 mg·min/mL at one day within the same treatment cycle,to a patient suffering from advanced or metastatic solid tumours.
  • 4. The method according to claim 2 or 3, wherein the treatment cycle is 14, 21 or 28 days.
  • 5. The method according to claim 2, wherein Volasertib and Cisplatin are administered at the same day.
  • 6. The method according to claim 3, wherein Volasertib and Carboplatin are administered at the same day.
  • 7. The method according to claim 5, wherein Volasertib and Cisplatin are administered at the same time.
  • 8. The method according to claim 6, wherein Volasertib and Carboplatin are administered at the same time.
Priority Claims (1)
Number Date Country Kind
11166365 May 2011 EP regional
US Referenced Citations (113)
Number Name Date Kind
4870175 Suzuki et al. Sep 1989 A
4957922 Lammens et al. Sep 1990 A
5043270 Abrams et al. Aug 1991 A
5167949 Ferrand et al. Dec 1992 A
5198547 Bailey et al. Mar 1993 A
5424311 Billhardt-Troughton et al. Jun 1995 A
5698556 Chan Dec 1997 A
6096924 Studer et al. Aug 2000 A
6156766 Arita et al. Dec 2000 A
6174895 Kleinman Jan 2001 B1
6605255 Kroll et al. Aug 2003 B2
6806272 Bauer et al. Oct 2004 B2
6861422 Hoffmann et al. Mar 2005 B2
6875868 Bonnert et al. Apr 2005 B2
6960589 Cowart et al. Nov 2005 B2
7238807 Duran et al. Jul 2007 B2
7241889 Hoffmann et al. Jul 2007 B2
7332491 Grauert et al. Feb 2008 B2
7371753 Stadtmueller et al. May 2008 B2
7414053 Grauert et al. Aug 2008 B2
7439358 Linz et al. Oct 2008 B2
7547780 Grauert et al. Jun 2009 B2
7625899 Hoffmann et al. Dec 2009 B2
7626019 Duran et al. Dec 2009 B2
7629460 Grauert et al. Dec 2009 B2
7638627 Kankan et al. Dec 2009 B2
7700769 Grauert et al. Apr 2010 B2
7723517 Grauert et al. May 2010 B2
7728134 Linz et al. Jun 2010 B2
7750152 Hoffman et al. Jul 2010 B2
7759347 Hoffmann Jul 2010 B2
7759485 Linz et al. Jul 2010 B2
7807831 Grauert et al. Oct 2010 B2
7816530 Grauert Oct 2010 B2
8003786 Hoffmann et al. Aug 2011 B2
8034816 Linz et al. Oct 2011 B2
8058270 Munzert et al. Nov 2011 B2
8138341 Linz et al. Mar 2012 B2
8138373 Linz et al. Mar 2012 B2
8143247 Munzert et al. Mar 2012 B2
8188086 Linz et al. May 2012 B2
8193188 Hoffmann et al. Jun 2012 B2
8202867 Linz et al. Jun 2012 B2
8329695 Linz et al. Dec 2012 B2
20020183292 Pairet et al. Dec 2002 A1
20020183293 Banerjee et al. Dec 2002 A1
20030130286 Denny et al. Jul 2003 A1
20030162790 Cowart et al. Aug 2003 A1
20040024205 Borredon et al. Feb 2004 A1
20040029885 Bauer et al. Feb 2004 A1
20040127504 Cowart et al. Jul 2004 A1
20040147524 Bauer et al. Jul 2004 A1
20040176380 Hoffmann et al. Sep 2004 A1
20050014760 Hoffmann et al. Jan 2005 A1
20050014761 Hoffmann et al. Jan 2005 A1
20050148501 Palmer et al. Jul 2005 A1
20050159414 Nickolaus et al. Jul 2005 A1
20050165010 Nickolaus et al. Jul 2005 A1
20060004014 Hoffmann et al. Jan 2006 A1
20060009457 Hoffmann et al. Jan 2006 A1
20060025411 Hoffmann et al. Feb 2006 A1
20060035902 Linz et al. Feb 2006 A1
20060035903 Mohr et al. Feb 2006 A1
20060046989 Grauert et al. Mar 2006 A1
20060047118 Stadtmueller et al. Mar 2006 A1
20060052383 Grauert et al. Mar 2006 A1
20060058311 Munzert et al. Mar 2006 A1
20060063735 Redkar et al. Mar 2006 A1
20060074088 Munzert et al. Apr 2006 A1
20060079503 Schwede et al. Apr 2006 A1
20070043055 Maier et al. Feb 2007 A1
20070117776 Lyons May 2007 A1
20070208027 Duran et al. Sep 2007 A1
20070213528 Duran et al. Sep 2007 A1
20070213529 Duran et al. Sep 2007 A1
20070213530 Duran et al. Sep 2007 A1
20070213531 Duran et al. Sep 2007 A1
20070213534 Duran et al. Sep 2007 A1
20070219369 Duran et al. Sep 2007 A1
20080108812 Grauert et al. May 2008 A1
20080113992 Grauert et al. May 2008 A1
20080171747 Hoffman et al. Jul 2008 A1
20080177066 Linz et al. Jul 2008 A1
20080194818 Grauert et al. Aug 2008 A1
20080221099 Munzert et al. Sep 2008 A1
20080293944 Hoffmann et al. Nov 2008 A1
20080319190 Grauert et al. Dec 2008 A1
20080319192 Grauert et al. Dec 2008 A1
20080319193 Grauert et al. Dec 2008 A1
20090018333 Grauert et al. Jan 2009 A1
20090023733 Cage et al. Jan 2009 A1
20090029990 Maier et al. Jan 2009 A1
20090030004 Linz et al. Jan 2009 A1
20090124628 Hoffmann et al. May 2009 A1
20090143379 Mohr et al. Jun 2009 A1
20090238828 Munzert et al. Sep 2009 A1
20090280115 Maier et al. Nov 2009 A1
20090298840 Linz et al. Dec 2009 A1
20090306101 Solca et al. Dec 2009 A1
20100029642 Hoffmann et al. Feb 2010 A1
20100179134 Singh et al. Jul 2010 A1
20100249412 Linz et al. Sep 2010 A1
20100249458 Linz et al. Sep 2010 A1
20100280037 Linz et al. Nov 2010 A1
20100324288 Hoffmann et al. Dec 2010 A1
20110046176 Moore, II et al. Feb 2011 A1
20120107312 Munzert et al. May 2012 A1
20120214995 Linz et al. Aug 2012 A1
20120238754 Schnaubelt et al. Sep 2012 A1
20120295864 Taube et al. Nov 2012 A1
20120296091 Sieger et al. Nov 2012 A1
20120329803 Linz et al. Dec 2012 A1
20130012465 Haslinger et al. Jan 2013 A1
Foreign Referenced Citations (48)
Number Date Country
2458699 Mar 2003 CA
2517020 Sep 2004 CA
2517010 Nov 2004 CA
2576290 Feb 2006 CA
143478 Jun 1985 EP
347146 Dec 1989 EP
399856 Nov 1990 EP
429149 May 1991 EP
2287583 Dec 2007 ES
2009169737 Jun 1997 JP
2002125451 Jan 2004 RU
9608537 Mar 1996 WO
9609045 Mar 1996 WO
9634867 Nov 1996 WO
9636597 Nov 1996 WO
9811893 Mar 1998 WO
0119825 Mar 2001 WO
0170741 Sep 2001 WO
0178732 Oct 2001 WO
02057261 Jul 2002 WO
02076954 Oct 2002 WO
02076985 Oct 2002 WO
03020722 Mar 2003 WO
03093249 Nov 2003 WO
2004014899 Feb 2004 WO
2004024728 Mar 2004 WO
2004076454 Sep 2004 WO
2004093848 Nov 2004 WO
2005067935 Jul 2005 WO
2006005510 Jan 2006 WO
2006018182 Feb 2006 WO
2006018185 Feb 2006 WO
2006018220 Feb 2006 WO
2006018221 Feb 2006 WO
2006021378 Mar 2006 WO
2006021379 Mar 2006 WO
2006021547 Mar 2006 WO
2007014838 Feb 2007 WO
2007054551 May 2007 WO
2007090844 Aug 2007 WO
2009019205 Feb 2009 WO
2009112524 Sep 2009 WO
2010111172 Sep 2010 WO
2011101369 Aug 2011 WO
2012049153 Apr 2012 WO
2012072505 Jun 2012 WO
2012156283 Nov 2012 WO
2012156380 Nov 2012 WO
Non-Patent Literature Citations (136)
Entry
Rudolph et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity Clin Cancer Res. May 2009.
Schoffski et al. (Polo-Like Kinase (PLK) Inhibitors in Preclinical and Early Clinical Development in Oncology, The Oncologist 2009, 14:559-570.
Rudolph et al. “BI 6727, A polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity,” Clin Cancer Res. 2009, vol. 15, No. 9, pp. 3094-3102.
Awada et al. “Phase I trial of volasertib, a polo-like kinase inhibitor, plus platinum agents in solid tumors: safety, pharmacokinetics and activity.” Invest New Drug, 2015, vol. 33, Issue 3, pp. 611-620.
Ahlenius, T. List of cardiovascular disorder/diseases. Ahlenius, Karolinska Institutet. Stockholm, Sweden. Cardiovascular Diseases, p. 1-34, Apr. 2007.
Ahmad, N. “Polo-like kinase (Plk) 1: a novel target for the treatment of prostate cancer”. The FASEB Journal. 2004, 18:5-7. Dept of Dermatology, Univ. Wisconsin, pp. 5-7.
Arnold, K. “Collaboration to play key role in NCI's future, director says”. Journal of the National Cancer Institute, Jun. 5, 2002, pp. 790-792, vol. 94, No. 11.
BBC News/Health, Killer Breast Cancern Therapy Hope, www.newsvote.bbc/co./uk, Published Jan. 21, 2006.
Bennett, J.C., et al., “Textbook of Medicine”, Part XIV Oncology, 1997.
Blain, S. W. et al., “Differential interaction of the cyclin-dependent kinase (Cdk) Inhibitor p27KIP with cyclin A-Cdk2 and cyclin D2-Cdk4”. The Journal of Biological Chemistry, vol. 272, No. 41, Issue Oct. 10, 1997, pp. 25862-25872.
Bug, G. et al., “Phase I/II Study of BI6727 (volasertib), n Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, in Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 in Combination with Low-dose Cytarabine”. Blood, vol. 116, No. 21, Nov. 19, 2010, p. 1359, American Socieity of Hematology (ASH); Orlando, FL, Dec. 2010.
Chen, J.X. et al., “Parallel differentiated recognition of ketones and acetals”. Angewandte Chemie Int. Ed, vol. 37, Issue 1/2, p. 91-93, 1998.
Eurasian Opinion, Appln No. 2007/00389/28, Maly Slatoustinsky per., d.10, kv.15, 101000 Moscow, Russia, “EVROMARKPAT”, 2007.
Ghandi, L., et al., “An Open-Label Phase II Trial of the PLK Inhibitor BI 2536 in Patients with Sensitive Relapse Small Cell Lung Cancer”. ASCO Meeting 2009.
Goodman-Gilman's “The Pharmacological Basis of Therapeutics”. Ninth edition, 1996, pp. 1225-1271.
Ito, Y., et al., “Polo-like kinase 1 (PLK) expression is associated with cell proliferative activity and cdc2 expression in malignant-lymphoma of the thyroid”. Anticancer Research, 2004, vol. 24, No. 1, pp. 259-263.
Jaworska, J., et al., “Review of methods for assessing the applicability domains of SARS and QSARS”. Sponsor: The European Commission—Joint Research Ctr., Institute for Health and Consumer Protection—ECVAM, Italy, 2004.
Kashima, M. K. et al., “Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas”. NCBI, PubMed, 2005.
Kimball, S. D. et al., “Cell cycle kinases and checkpoint regulation in cancer”. Annual Reports in Medicinal Chemistry, 36, Chapter 14, 2001, pp. 139-148.
Kummer B, et al., “Combination of Radiation and Polo-like Kinase 1 Inhibition with BI6727 in tumour model A431”. Vortrag. 20. Symposium ,,Experimentelle Strahlentherapie and klinische Strahlenbiologie, Exp. Strahlenther. Klin. Strahlenbiol. 20: 93-96 (2011) (Lecture 20, Symposium Experimental Radiation Therapy and Clinical Radiation Biology.).
Kummer, B. et al., Presentation: “Combination of irradiation and polo-like kinase 1 inhibition with BI 6727 in tumour model A 431”. OncoRay—National Centre for Radiation Research in Oncology, Dresden 2011, Experimental Radiotherapy and Clinical Radiobiology.
Leukemia & Lymphoma Society—Disease Information-Lymphoma. www.leukemia-lymphoma.org/all—page?item—id-7030, 2008.
Leukemia & Lymphoma Society—Disease Information. www.leukemia-lymphoma.org/all—page?item—id-7026, 2008.
Marko, D. et al., “Intracellular localization of 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine in membrane structures impeding the inhibition of cytosolic cyclic AMP-specific phosphodiesterase”. Biochemical Pharmacology, 63, 2002, pp. 669-676.
Mashkovkii, M.D., “Medicaments”. Moscow, Novaja Volna, 2001, vol. 1, p. 11.
Mashkovskii, M.D. “Drugs”, Handbook for Doctors, 1993, Part I, Ch.1, p. 8.
Masuda, Y. et al., “B-Hydroxyisovalerylshikonin induces apoptosis in human leukemia cells by inhibiting the activity of a polo-like kinase 1 (PLK)”. 2003, Oncogene, 22, pp. 1012-1023.
Mayer, SF, et al., “Enzyme-initiated domino (cascase) reactions”. Chem. Soc. Rev, 2001, p. 332-339.
MedlinePlus: Bacterial Infections. www.nim.nih.gov/medlineplus/print/bacterialinfections.htm, date last updated Mar. 25, 2009.
MedlinePlus: Viral Infections. www.nim.nih.gov/medlineplus/print/viralinfections.htm, date last updated Feb. 11, 2009.
Merck Manual of Medical Information—Home Edition, Section 17. “Parasitic Infections”. Chapter 184, 2003.
Mikhailov, I.B., Principles of Rational Pharmacotherapy. Handbook for clinical pharmacology for students of pediatric and medical faculties of medical high schools, St. Petersburg, Russia, “Foliant”, 1999, p. 25.
Mito, K., et al., “Expression of polo-like kinase (PLK1) in non-Hodgkin's lymphomas”. NCBI, PubMed, 2005, Leuk. Lymphoma, 46(2), pp. 251-231.
Nagao, K. et al., “Effect of MX-68 on airway inflammation and hyperresponsiveness in mice and guinea-pigs”. Journal of Pharmacy and Pharmacology, JPP 2004, 56, pp. 187-196.
National Institute of Neurological Disorders, Index Stroke, 2006.
Neidle, S. ed., “Cancer Drug Design and Discovery”, Elsevier/Academic Press, 2008, p. 427-431.
Norman, P. “PDE4 inhibitors”. Ashley Publications Ltd., Expert Opinions Ther. Patents, 1999, pp. 1101-1118.
Office Action mailed Dec. 10, 2003 for U.S. Appl. No. 10/226,710, filed Aug. 23, 2002. Inventor: Eckhart Bauer.
Office Action mailed Apr. 28, 2004 for U.S. Appl. No. 10/374,876, filed Feb. 26, 2003. Inventor: Matthias Hoffmann.
Ohio Dept of Health, “Brain and Other Central Nervous System Cancer in Ohio, 1997-2001”. Sep. 2004, pp. 1-4.
Organic Chemistry, Grupo Editorial Iberoamerica, Section 13, 3, pp. 301-302, 1983 (best copy available in Spanish).
Rocha Lima, C.M. et al. “Randomized phase II trial of gemcitabine plus irinotecan or docetaxel uin stage IIIB or stage IV NSCLC” Annals of Oncology, 15(3), p. 410-418, 2004.
Rudolph, D. et al., “430 Poster Characterization of BI 6727, a novel Polo-like kinase inhibitor with a distinct pharmacokinetic profile and efficacy in a model of taxane-resistant colon cancer”. European Journal of Cancer. Supplement, Pergamon, Oxford, GB, vol. 6, No. 12, Oct. 1, 2008, p. 135. [retrieved on Oct. 1, 2008].
Santing, R. E. et al., “Brochodilatory and anti-inflammatory properties of inhaled selective phosphodiesterase inhibitors in a guinea pig model of allergic asthma”. European Journal of Pharmacology, 429, 2001, pp. 335-344.
Science, vol. 310, Oct. 21, 2005, p. 409, Chemistry: One After Another.
Snyder, J. S. et al., “Common bacteria whose susceptibility to antimicrobials is no longer predictable”. NCBI, PubMed, 2000, Le Journal Medical Libanais (The Lebanse Medical Journal), 48, pp. 208-214.
Sugar, A. M. et al., “Comparison of three methods of antifungal susceptibility testing with the proposed NCCLS standard broth macrodilution assay: lack of effect of phenol red”. Mycology, Diagn Microbiol. Infect. Dis. 1995, 21—pp. 129-133.
Takai, N. et al., “Polo-like kinases (PLKs) and cancer”. Oncogene , 2005, 24, pp. 287-291.
Tenbrink, R. E. et al., “Antagonist, partial agonist, and full agonist imidazo[1,5-a]quinoxaline amides and carbamates acting through the BABA/Benzodiazepine receptor”. J. Med. Chem. 1994, 37, pp. 758-768.
Turner, W.W.et al., “Recent advances in the medicinal chemistry of antifungal agents”. Current Pharmacutical Design, 1996, 2, pp. 209-224.
Verschuren, E.W. et al., “The cell cycle and how it is steered by Kaposi's sarcoma-associated herpesvirus cyclin”. Journal of General Virology, 2004, 85, pp. 1347-1361.
Voskoglou-Nomikos, T. et al., “Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models”. Clinical Cancer Research vol. 9, 2003, pp. 4227-4239.
Wagner, B. et al, “7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidino-pteridine, a potent inhibitor of cAMP-specific phosphodiesterase, enhancing nuclear protein binding to the CRE consensus sequence in human tumour cells”, Biochemical Pharmacology, Pergamon, Oxford, GB, 2002, pp. 659-668.
Wolf, D. E.et al., “The structure of rhizopterin”. Contribution from the Research Labs of Merck and Co. Inc. Nov. 1947, Journal of American Chem. Soc., vol. 69, pp. 2753- 2759. XP002352205.
Rylander, P.N. “Hydrgenation Methods”. 1985, Chapter 5, 6, 7.
Rylander, P.N., “Hydrogenation Methods”. 1985, Chapters 1, 2.
Savelli, F. et al., “Heterotricyclic system Part II—synthesis of new pyrido[1′2′:4,5]pyrazino[3,2-d] pyrimidines”. Bollettino Chimico Farmaceutico, 131(8), Sep. 1992, pp. 309-312.
Seetharam, M. et al., “Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na.” Leukemia Research, 2012, vol. 36, pp. 98-103.
Serajuddin, Abu T.M., “Salt formation to improve durg solubility”, Advanced Drug Delivery Reviews, 59, 2007, 603-616.
Souillac, P. et al., “Characterization of delivery systems, differential scanning calorimetry”. (In Encyclopedia of Controlled Drug Delivery), 1999, John Wiley & Sons, pp. 212-227.
Turner, S., “The Design of Organic Syntheses”. Elsevier, 1976, pp. 10 and 149.
Vippagunta, S. R. et al., “Crystalline solids”. Advanced Drug Delivery Reviews, 48, 2001, pp. 3-26.
Visiting Nurse Association of America. www.vnaa.org/gen/Germ—Protection—Center—Cold—and—Flu—Resources,html, 2009.
Wagner, G. et al. “Synthesis of new phrido[3′,2′:4,5] thieno '3,2-d] 1,2,3-triazine derivatives as antianaphylactics”. Biosciences Dept of the University of Leipzig, Pharmazie (Pharmacy), 48, vol. 7,1993, pp. 514-518.
Webster's Comprehensive Dictionary, 1996, pp. 1013-1014.
Wikipedia. “Melting Point”, Jan 17, 2007. http://en.wikipedia.org/wiki/Melting—point.
X-ray Diffraction—Factors that affect d's and I's. [Downloaded from the internet Mar. 9, 2011, URL: http://www.gly.uga.edu/Schroeder/geol6550/XRD.html].
Berg, T. et al., “Polo-like kinases in AML” Expert Opinion on Investigational Drugs, 2012, vol. 21, No. 8, pp. 1069-1074.
Boulikas, T. et al., “Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (Review).” Oncology Reports, 2004, vol. 11, pp. 559-595.
Bug, G. et al., “Phase I/II Study of BI 6727 (volasertib), An Intravenous Polo-Like Kinase-1 (Plk1) Inhibitor, In Patients with Acute Myeloid Leukemia (AML): Results of the Dose Finding for BI 6727 in Combination with Low-Dose Cytarabine.” Blood, 2010, vol. 116, pp. 1-2.
Clinical Trials: NCT01348347. B16727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients with Advanced Soliid Tumours. Apr. 29, 2011 [Retrieved from the Internet: URL: http://www.clinicaltrials.gov./ct2/show/NCT01348347?term=volasertib&rank=1] retrieved Jul. 16, 2012.
Ellis, P.M. et al., “A Phase I Open-Label Dose-Escalation Study of Intravenous BI 2536 Together with Pemetrexed in Previously Treated Patients with Non-Small-Cell Lung Cancer” Clinical Lung Cancer, 2012, p. 1-9.
Gil, T. et al., “Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.” 2010 ASCO Annual Meeting, Journal of Clinical Oncology, Poster Abstract No. 3061.
International Search Report and Written Opinion for PCT/EP2011/071008 mailed Feb. 28, 2012.
International Search Report and Written Opinion for PCT/EP2012/058704 mailed Aug. 8, 2012.
International Search Report and Written Opinion for PCT/EP2014/065937 mailed Oct. 6, 2014.
International Search Report and Written Opinion for PCT/EP2014/065938 mailed on Sep. 9, 2014.
Lin, C-C et al., “A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies.” British Journal of Cancer, 2014, pp. 1-7.
Medema et al.; Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCL; Clinical Cancer Research; 2011; vol. 17; No. 20; pp. 6459-6466.
Mross, K. et al., A randomised phase II trial of the polo-like kinase inhibitor BI 2536 in chemo-naieve patients with unresectable exocrine adenocarcinoma of the pancreas—a study within the Central European Society Anticancer Drug research (CESAR) collaaborative work. British Journal of Cancer, 2012, p. 1-7.
Phys. Org. “New way of inhibiting cell cycle shows promise.” Oct. 22, 2008, pp. 1-2. http://phys.org/news143890171.html.
Schoffski, P. et al., “A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumors.” European Journal of Cancer, 2012, vol. 48, pp. 179-186.
Schoffski, P., “Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology”, The Oncologist, vol. 14, 2009, pp. 559-570.
Schoffski, P., et al., “A phase I single dose escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumours”, EJC Supplement, vol. 6. No. 12, Oct. 2008, p. 14-15.
Xu, W-J., “Efficient Inhibition of Human Colorectal Carcinoma Growth by RNA Interference Targeting Polo-Like Kinase 1 In Vitro and In Vivo.” Cancer Biotherapy and Radiopharmaceuticals, 2011, vol. 26, No. 4, pp. 427-436.
“Salt Forms of Drug Absorption”, Swarbrick, et al. editors, Encyclopedia of Pharm. Tech. 13 Marcel Dekker, NY, 1996, 453-499.
Abstract in English for JP09169737, Date of Publication: Jun. 30, 1997, Applicant Tosoh Corp, Inventor: K. Hiroyuki, Title: Production of N-Methylimidazoles. Date filed: Dec. 21, 1995.
ACPS Meeting, Background Information. “Scientific considerations of plymorphism in pharmaceutical solids: abbreviated new drug applications”. Oct. 2002.
Badawy, S. I. et al., “Sale Selection for Phamaceutical Compounds”, Preformulation in Solid Dosage Form Develolpment, Infoa Healthcare 2008, Chapter 2.3, 63-80.
Bastin, R. J. et al., “Salt Selection and Optimisation Procedures for Pharmaceutical New Chemical Entities”, Organic Process Research and Development, 2000, 4,427-435.
Benetatos, L. et al., “Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions.” Annals of Hematology, 2011, vol. 90, No. 9, pp. 1037-1045.
Beshore, D.C.et al., “Preparation of Substituted Piperazinones via Tandem Reductive Amination-N.N-Acyl Transfer)-Cyclization”. Organic Letters, 2002, vol. 4, No. 7, p. 1201-1204.
Cancer Drug Design and Discovery, Stephen Neidle, Ed. (Elsevier/Academic Press, 2006), p. 427-431.
Christoph, D. et al., “Polo-like kinase 1 inhibitors in mono-and combination therapies: a new strategy for treating malignancies.” Expert Review of Anticancer Therapy, 2011, vol. 11, No. 7, pp. 1115-1130.
Dipolar aprotic solvent. Exhibit A, IUPAC Compendium of Chemical Terminology, 2nd Edition, 1997.
Doerwald, F.Z. Book Wiley-VCH Verlag GmbH & Co. KGaA, “Side reactions in organice synthesis: A Guide to Successful Synthesis Design”. 2005.
Dyson, G, et al. “The Chemistry of Synthetic Drugs”. 1964, p. 12-19.
Expert Scientific Group on Phase One Clinical Trials, Final Report, Nov. 30, 2006, pC1, C35-C38.
Ferrand, G., et al., “Synthesis and potential antiallergic activity of new pteridinones and related compounds”. Eur. J. Med. Chem, 31, 1996, pp. 273-280. XP—2246920.
Giron, G. “Thernal analysis and calorimetric methods in the characterization of plymorphs and solvates”. Thermochimica Acta 248, 1995, pp. 1-59.
Goodman & Gilman's The Pharmacological Basis of Therapeutics, Tenth Edition, Chapter 1 “Pharmacokinetics: The Dynamics of Drug Absorption, Distribution, and Elimination.” 2001, pp. 3-29.
Goodman and Gilman 9th Edition; 1996; pp. 1225-1232 and 1269-1271.
Gould, P. L., “Salt selection for basic drugs”, International Journal of Pharmaceutics, 33(1986), 201-217.
Gura, T. “Cancer Models: Systems for Identifying New Drugs are Often Faulty”. Science, Nov. 7, 1997, vol. 278, No. 5340—p. 1041-1042.
International Seach Report for PCT/EP2007/051139 mailed May 29, 2007.
International Search Report and Written Opinion for PCT/EP2005/008623 mailed Nov. 23, 2005.
International Search Report and Written Opinion for PCT/EP2005/008626 mailed Feb. 10, 2006.
International Search Report and Written Opinion for PCT/EP2008/060112 mailed Nov. 6, 2008.
International Search Report and Written Opinion for PCT/EP2011/052280 mailed Apr. 29, 2011.
International Search Report and Written Opinion for PCT/EP2011/067696 mailed Nov. 4, 2011.
International Search Report and Written Opinion for PCT/EP2014/065939 mailed Sep. 9, 2014.
International Search Report for PCT/EP03/01935 mailed Jul. 23, 2003.
International Search Report for EP2005/007347 mailed Oct. 18, 2005.
International Search Report for PCT/EP2005/006404 mailed Nov. 14, 2005.
International Search Report for PCT/EP2005/007532 mailed Oct. 6, 2005.
International Search Report for PCT/EP2005/008734. mailed Aug. 25, 2006.
International Search Report for PCT/EP2005/008735 mailed Dec. 8, 2005.
International Search Report for PCT/EP2005/008736 mailed Nov. 30, 2005.
International Search Report for PCT/EP2005/008990 mailed Dec. 13, 2005.
International Search Report for PCT/EP2005/008991 mailed Dec. 15, 2005.
International Search Report for PCT/EP2005/054096 mailed Jan. 24, 2006.
International Search Report for PCT/EP2005/054099 mailed Dec. 15, 2005.
International Search Report for PCT/EP2005/056291 mailed Mar. 21, 2006.
International Search Report for PCT/EP2006/064305 mailed Oct. 16, 2006.
Jamieson, C. et al., “Application of ReactArray Robotics and Design of Experiments Techniques in Optimisation of Supported Reagent Chemistry”. Org. Proc. Res. & Dev., 2002, 6, pp. 823-825.
Kamb, A. “What's wrong with our cancer models?”. Nature Reviews Drug Discovery, vol. 4, Feb. 2005, pp. 161-165.
Kola, I. et al., “Can the phamaceutical industry reduce attrition rates?” Nature Reviews Drug Discovery, vol. 3, Aug. 2004, pp. 711-715.
Krause, M. et al., “Combination of Radiation and Polo-like Kinase 1 Inhibition with BI 6727 in tumour model A431”. Strahlenther Onkol, 187, S1, 53 (v17-6), 2011.
Leaf, C. et al., “Why are we losing the war on cancer (and how to win it)”. Health Administrator, vol. XVII, No. 1, 2005, pp. 172-183.
Morris, K.R. et al., “An integrated approach to the selection of optimal salt form for a new drug candidate”, International Journal of Pharmaceutics, 105, 1994, 209-217.
Neau, S. H., Pharmaceutical Salts, CRC Press, 2008, Ch 17, pp. 417-435.
Roberts, Jr., T. G. et al. “Trends in the Risks and Benefits to Patients with Cancer Participating in Phase 1 Clinical Trials”. JAMA, Nov. 3, 2004, vol. 292, No. 17, pp. 2130-2140.
Rylander, P.N. “Hydrgenation Methods”. 1985, Chapter 13.
Rylander, P.N. “Hydrgenation Methods”. 1985, Chapters 3, 4.
Rylander, P.N. “Hydrgenation Methods”. 1985, Chapters 8, 9, 10, 11.
International Search Report and Written Opinion for PCT/EP2015/072386 mailed Dec. 2, 2015.
Related Publications (1)
Number Date Country
20130122111 A1 May 2013 US